Remifentanil pre-treatment has been reported to decrease the incidence of rocuronium injection-associated withdrawal movement. This study was designed to explore the site of action of remifentanil for reducing withdrawal response during rocuronium injection in children. Ninety-six paediatric patients were randomly assigned to three groups. After induction of anaesthesia with 5 mg/kg 2.5% thiopental sodium, 2 ml saline (placebo group) or 0.5 µg/kg remifentanil (group R), was injected intravenously 1 min before 0.6 mg/kg rocuronium. In a third group (group R′), the venous retention of 0.5 µg/kg remifentanil was maintained for 30 s followed by tourniquet release and injection of 0.6 mg/kg rocuronium. Withdrawal response was graded using a four-point scale. The incidence of withdrawal movement after rocuronium administration was 94%, 22% and 81% in the placebo, R, and R′ groups, respectively. This study demonstrated that the pre-treatment effect of remifentanil for reducing rocuronium-associated withdrawal response occurs mainly through a central action.
Introduction
Injection of rocuronium is associated with generalized patient movement or withdrawal of the arm, which is presumed to be due to pain at the injection site. 1 -4 Withdrawal movements may induce pulmonary aspiration in children 5 and cause dislocation or displacement of the intravenous (i.v.) catheter, resulting in difficulty administering additional drugs. The rocuronium-induced withdrawal response can be attenuated or abolished by clinical treatments similar to those used for the prevention of pain on propofol injection, such as locally JR Yoon, Y Jeon, Y Yoo et al. Remifentanil prevention of withdrawal response after rocuronium administration administered i.v. anaesthetics or opioids. 6 -10 Remifentanil pre-treatment has been shown to decrease the incidence of rocuronium-induced withdrawal movement. 6 It has been suggested that this pre-treatment acts through either a central or a peripheral effect, since opioid receptors are present not only in dorsal root ganglia and central terminals of primary afferent nerves, but also in peripheral sensory nerve fibres and their terminals. 6, 11 To date, no reports elucidate this mechanism. The present study was, therefore, designed to explore the site of action of remifentanil for reducing the withdrawal associated with the injection of rocuronium in children. A venous occlusion technique was used and an adequate time interval between injection of remifentanil and rocuronium was allowed.
Patients and methods

PATIENTS
This prospective, randomized study was approved by the Institutional Ethics Committee of the University of Korea Medical Centre and written informed consent was obtained from parents prior to the study. Patients aged 3 -10 years with American Society of Anesthesiology physical status I or II 12 , who were attending the University of Korea Medical Centre between March and August 2008 for elective surgery with general anaesthesia, were randomly assigned into one of three study groups according to a computer-generated randomization schedule. Patients with asthma, neurological deficits, psychiatric disorders, known allergies to opioids, those who had received sedative or analgesic medication within 24 h before surgery and those requiring a rapid-sequence induction were excluded.
STUDY DESIGN
Patients were not pre-medicated prior to surgery. A 24-gauge cannula was placed in a dorsal vein on the patient's hand and the position was confirmed by a gravitational free flow of dextrose/saline infusion. All patients were monitored via electrocardiogram, pulse oximetry and noninvasive arterial pressure on arrival at the operating theatre. After pre-oxygenation, anaesthesia was induced with 5 mg/kg 2.5% thiopental sodium followed by a free flow of i.v. fluid until loss of consciousness, assessed by loss of normal eye reflexes. Mask ventilation was initiated with 100% oxygen once the patient became unconscious and apnoeic. After 10 s, patients in group P (placebo) received 2 ml saline, and those in group R received 0.5 µg/kg remifentanil (Ultiva ® , GlaxoSmithKline, Uxbridge, UK) i.v., over 10 s. After a further 1 min, 0.6 mg/kg 1% rocuronium (Esmeron ® ; Organon, Oss, The Netherlands) i.v. was injected over 5 s in both groups. In a third group (group R′), a pneumatic tourniquet was placed on the upper arm to produce a venous occlusion before patients received 0.5 µg/kg remifentanil i.v. over 10 s. After 30 s, the occlusion was released and rocuronium was injected through the i.v. cannula, as in groups P and R.
An investigator (J.H.A) who did not know the purpose of this study graded the patient response to rocuronium injection. The grading was as follows, and as previously described: 13 1, no response; 2, movement at the wrist only; 3, movement/withdrawal involving arm only (elbow/shoulder); and 4, generalized response, movement/withdrawal in more than one extremity.
STATISTICAL ANALYSES
Based on an estimated incidence of 80%, a power analysis indicated that a sample size of 30 in each group was sufficient to have 80% power to detect a 50% difference in the JR Yoon, Y Jeon, Y Yoo et al. Remifentanil prevention of withdrawal response after rocuronium administration incidence of withdrawal movement between the three groups at a 95% significance level.
Statistical analysis was carried out using SAS software, version 8.1 (SAS Institute Inc., Cary, NC, USA) for Windows ® . Data are presented as number of patients or mean ± SD. Demographic data were compared using analysis of variance. The incidence of withdrawal movement was analysed using the χ 2 -test or Fisher's exact test. Statistical significance was defined as P < 0.05.
Results
A total of 96 patients were enrolled in the study. Aside from height, there were no significant differences in patient characteristics between the groups ( Table 1) .
The overall incidence of withdrawal response (combined incidence for patients with grade 2, 3 or 4 withdrawal movement) after rocuronium injection was 94%, 22% and 81% in groups P, R, and R′, respectively ( Table 2 ). The incidence of generalized movement (grade 4) was significantly lower, and the number of patients with no withdrawal response (grade 1) was significantly higher, in group R than in groups P or R' (P < 0.0001). The incidence of grade 4 generalized movement was significantly lower in group R′ than group P (P = 0.002). There was no significant difference in the overall incidence of withdrawal movement between groups P and R′.
Discussion
Remifentanil pre-treatment effectively attenuated rocuronium-associated withdrawal when there was no use of a tourniquet to induce venous occlusion, suggesting that the analgesic effect of remifentanil may have a primarily central action. A rocuronium-associated incidence of withdrawal of 83 -94% has previously been reported in paediatric patients, with severe withdrawal response (≥ arm withdrawal response) reported in 73% -88% of the patients, and generalized withdrawal response rates reported in 49 -51%. 6 -8 The present study demonstrated similar findings, with 81 -94% experiencing all levels of withdrawal and 44 -75% experiencing generalized movement in the placebo and remifentanil groups via venous occlusion.
Withdrawal movement due to rocuronium injection is known to be Data expressed as mean ± SD or number. a P < 0.05 vs group R′. Patients in group P (placebo) received 2 ml saline and those in group R received 0.5 µg/kg remifentanil intravenous (i.v.) injection over 10 s. After a further minute, 0.6 mg/kg 1% rocuronium i.v. was injected over 5 s in both groups. In group R′, a pneumatic tourniquet was placed on the upper arm to produce a venous occlusion before patients received 0.5 µg/kg remifentanil i.v. over 10 s; after 30 s, the occlusion was released and rocuronium was injected through the i.v. cannula as in groups P and R.
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associated with a severe burning pain lasting for approximately 10 -20 s. 1 -4 Although the pathophysiological mechanism of this pain is not clear, it has been suggested that it may be caused by the activation of nociceptors due to the osmolality or low pH of the solution. 14 Patients who received normal saline buffered to pH 4 or diluted rocuronium 0.5 mg/ml with an osmolality similar to the formulation used for rocuronium did not, however, complain of pain. 1, 15 It is also possible that either the release of local mediators, such as kinins, directly irritates venous nociceptors, or that the algogenic effect of aminosteroidal neuromuscular blocking drugs leads to a direct activation of C-nociceptors. 1, 16 Several reports using different drugs, with or without the tourniquet technique to prevent withdrawal reactions during rocuronium injection, have been published. 6 -10 The application of a venous tourniquet similar to the modified Bier block is useful for drugs with local anaesthetic properties 17 such as lidocaine, 10,13 ondansetron 18 or tramadol. 18 Meanwhile, drugs with a central action, such as morphine and fentanyl, need an adequate time interval to be delivered to the effect site. 9 Kim et al. 6 reported that pre-treatment with remifentanil (using a 1-min time interval) was effective in reducing the incidence of rocuronium-associated withdrawal movement in children. They suggested that this could be caused by a central effect, but were unable to exclude a peripheral effect, due to the distribution of opioid receptors. In the present study, a 1min interval between remifentanil and rocuronium injections was used in group R because the effect site concentration of remifentanil peaks at 1 min. 19 Venous occlusion using a rubber tourniquet was used to examine the peripheral action of remifentanil in group R′, with 30 s chosen as the ideal duration, based on a previous meta-analysis. 20 The dose of 0.5 µg/kg remifentanil was determined based on previous studies by Batra et al., 21 and a bolus administration method was chosen to exclude the peripheral effect that can be induced by infusion. Thiopental rather than propofol was used as an induction agent in the present study, in order to exclude the injection pain associated with propofol. 22 Remifentanil pre-treatment in group R 6 It is likely that pre-treatment with remifentanil results in a deeper level of anaesthesia, which increases the pain threshold, leading to a decreased incidence of withdrawal movement. 6 There was no significant difference in the incidence of withdrawal movement between group R′ and the placebo group, even though the incidence of generalized movement in group R′ was lower than that in the placebo group. This finding is consistent with the assumption that remifentanil has a central analgesic effect in reducing the injection pain associated with rocuronium, as seen in its interactions with fentanyl. 9 This suggests that adequate time should be allowed for the onset of the drug effect when using opioids such as remifentanil to prevent injection pain.
In conclusion, this study demonstrated that remifentanil pre-treatment decreased the incidence of rocuronium-associated withdrawal movement, mainly via a central effect. Remifentanil should be injected 1 min before rocuronium in order effectively to prevent rocuronium-associated withdrawal movement.
